The Febrile Neutropenia (FN) Market is distinctly segmented primarily by treatment type: Prophylactic and Therapeutic. The Prophylactic segment, dominated by Granulocyte Colony-Stimulating Factors (G-CSFs), holds the largest market share and provides the financial stability for the entire industry. This segment is driven by the standardized clinical guidelines that advocate for the routine use...